ENDRA Life Sciences closed at $4.83 on Nov 3, up 0.63%, 27.9% below its 52-week closing high. Volume of 2.0K shares was 0.16× its 20-day average (below normal).
Split-adjusted performance: -23.5% over one month, -0.4% over six months, -8.0% over one year.
Short interest was 24.1K shares at the Oct 15 settlement, down 14.7% from the prior report (1.7% of float, 1.4 days to cover).
No reported quarters with price history yet.
Percentile among 22 companies (100 = best)
Industry medians: 6-month return −9.2%, revenue growth +13.9%, net margin −44.6%, P/E 21.7×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NDRAENDRA Life Sciences | $4.83 | +0.63% | −0.4% | — | — | — | $7.2M | |
| IRIXIridex | $0.7200 | −0.20% | −31.4% | −7.4% | −10.1% | — | $12.6M | Compare |
| NUWENuwellis | $5.16 | −0.37% | −98.5% | +14.1% | −245.1% | — | $2.1M | Compare |
| QTIQT Imaging Holdings | $2.23 | +3.72% | −67.2% | +103.2% | −148.9% | — | $32.6M | Compare |
| NXLNexalin Technology | $1.50 | −0.33% | −86.1% | −82.8% | −18412.7% | — | $1.6M | Compare |
| STEXStreamex | $0.3751 | +0.59% | −59.1% | — | −9968.5% | — | $43.7M | Compare |
| POCIPrecision Optics | $4.78 | −0.42% | +3.9% | +42.0% | −1.2% | — | $52.6M | Compare |
| ECORelectroCore | $7.25 | +1.26% | +3.7% | +28.0% | −32.4% | — | $65.4M | Compare |
| HYPRHyperfine | $0.6861 | −5.33% | −59.9% | +44.8% | −238.2% | — | $72.8M | Compare |
No recent articles focused on ENDRA Life Sciences.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
